FLORENCE NWOKOYE: Open Payments
NPI 1447878863 · DECATUR, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,959 in 182 payments from 13 companies in 2025. Trend: 2023 $1,925 · 2024 $2,456 · 2025 $2,959
Food & beverage: $2,959
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 37 | $548 |
| Janssen Pharmaceuticals, Inc | 16 | $512 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 33 | $508 |
| Neurocrine BioSciences, Inc. | 17 | $500 |
| Supernus Pharmaceuticals, Inc. | 42 | $291 |
| Teva Pharmaceuticals USA, Inc. | 19 | $234 |
| Lundbeck LLC | 5 | $107 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Luye Pharma (USA) Ltd. | 2 | $40 |
Products named: COBENFY, INVEGA SUSTENNA, CAPLYTA, INGREZZA, Qelbree, AUSTEDO XR, REXULTI, TRINTELLIX.
Industry payments across TX — which companies pay providers there.
